Home > Concurrent Symposia Sessions > Immunotherapy vs. Immunosuppression
Concurrent Symposia Sessions
Wednesday, October 15, 2008
Natcher Conference Center
Symposia Session II
Balcony A
Immunotherapy vs. Immunosuppression |
10:30 a.m. - 1:30 p.m. |
---|
Chair: Arya Biragyn, NIA
Immunotherapies for autoimmune diseases and cancer appear to pursue two opposing goals. However, these two fields both concentrate on common processes, such as immunosuppression and immunotolerance. On one hand, therapy of autoimmune diseases is aimed at restoration of tolerance. On the other hand, the goal of cancer immunotherapy is to increase cancer immunogenicity and to circumvent immunosuppressive conditions and microenvironments. Thus, the aim of this mini-symposium is to bring expert investigators from both fields together to initiate an exchange of ideas beneficial for the treatment of both diseases. This session will also provide a rare opportunity to hear the most recent results and ideas on how to manipulate the immune system to augment or inhibit responses to self-antigens.
Program
Introduction
Arya Biragyn, NIA
Recent Developments in Human Cancer Immunotherapy
Steven A. Rosenberg, NCI
Apoptosis-linked Immunoregulation: Implications in Immunotherapy for Autoimmune Diseases and Cancer
Wanjun Chen, NIDCR
Cytokines Produced by NKT Cells and Autoimmune Disease
Rachel Caspi, NEI
Targeting Jak3
Kamran Choreschi, NIAMS
Combining Proteasome Inhibition with the Immunotherapy of Cancer
Tom Sayers, NCI
Tracking CD4 Treg Cells in Autoimmune Disease and Cancer
Xin Chen, NCI
Control of Breast Cancer Lung Metastasis via Chemokine Receptor CCR4 Targeting Strategies
Arya Biragyn, NIA